Brivaracetam as add-on treatment in patients with post-stroke epilepsy: real-world data from the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST)

Lattanzi, Simona; Canafoglia, Laura; Canevini, Maria Paola; Casciato, Sara; Irelli, Emanuele Cerulli; Chiesa, Valentina; Dainese, Filippo; Maria, G. De; Didato, Giuseppe; Gennaro, Giancarlo Di; Falcicchio, Giovanni; Fanella, Martina; Ferlazzo, Edoardo; Gangitano, Massimo; Neve, Angela La; Mecarelli, Oriano; Montalenti, Elisa; Morano, Alessandra; Piazza, Federico; Pizzanelli, Chiara; Pulitano, Patrizia; Ranzato, Federica; Rosati, Eleonora; Tassi, Laura; Bonaventura, Carlo Di; Alicino, Angela; Ascoli, Michele; Assenza, Giovanni; Avorio, Federica; Badioni, Valeria; Banfi, Paola; Bartolini, Emanuele; Basili, Luca Manfredi; Belcastro, Vincenzo; Beretta, Simone; Berto, Irene; Biggi, Martina; Billo, Giuseppe; Boero, Giovanni; Bonanni, Paolo; Bongorno, Jole; Brigo, Francesco; Caggia, Emanuele; Cagnetti, Claudia; Calvello, Carmen; Cesnik, Carlos E. S.; Chianale, Gigliola; Ciampanelli, Domenico; Ciuffini, Roberta; Cocito, Dario; Colella, Donato; Contento, Margerita; Costa, Cinzia; Cumbo, Eduardo; D’Aniello, Alfredo; Deleo, Francesco; DiFrancesco, Jacopo C.; Giacomo, Roberta Di; Liberto, Alessandra Di; Domina, Elisabetta; Dono, Fedele; Durante, Vania; Elia, Maurizio; Estraneo, Anna; Evangelista, Giacomo; Faedda, M. T.; Failli, Ylenia; Fallica, Elisa; Fattouch, Jinane; Ferrari, Alessandra; Ferreri, Florinda; Fisco, Giacomo; Fonti, Davide; Fortunato, Francesco; Foschi, Nicoletta; Francavilla, T.; Galli, Rosita; Gazzina, Stefano; Giallonardo, Anna Teresa; Giorgi, Filippo Sean; Giuliano, Loretta; Habetswallner, Francesco; Izzi, Francesca; Kassabian, Benedetta; Labate, Angelo; Luisi, Concetta; Magliani, Matteo; Maira, Giulia; Mari, Luisa; Marino, Daniela; Mascia, Addolorata; Mazzeo, Alessandra; Milano, Chiara; Meletti, Stefano; Nilo, Annacarmen; Orlando, Biagio; Paladin, Francesco; Pascarella, Maria Grazia; Pastori, Chiara; Pauletto, Giada; Peretti, Alessia; Perri, Gabriella; Pezzella, Marianna; Piccioli, Marta; Pignatta, Pietro; Pilolli, Nicola; Pisani, Francesco; Pisani, Laura Rosa; Placidi, Fabio; Pollicino, Patrizia; Porcella, Vittoria; Pradella, Silvia; Puligheddu, Monica; Quadri, Stefano; Quarato, Pier Paolo; Quintas, Rui; Renna, Rosaria; Rizzo, G.; Rum, A.; Salamone, Enrico Michele; Savastano, Ersilia; Sessa, Maria; Stokelj, David; Tartara, Elena; Tombini, Mario; Tumminelli, Gemma; Vaudano, Anna Elisabetta; Ventura, Maria; Viganò, Ilaria; Viglietta, Emanuela; Vignoli, Aglaia; Villani, Flavio; Zambrelli, Elena; Zummo, Leila

doi:10.1016/j.seizure.2022.03.007

Cited by 9 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most real-world research on BRV has focused on refractory epilepsy and only a few studies have provided preliminary insights about BRV use in special populations [4][5][6] and in the early stages of treatment [7]. There is, hence, little information about the effectiveness of BRV when it is administered as a first or second add-on therapy.…”

Section: Introductionmentioning

confidence: 99%

“…In randomized, placebo-controlled trials, BRV reduced seizure frequency when added to pre-existing antiseizure medications (ASMs) in patients with drug-resistant focal epilepsy [ 3 ]. Most real-world research on BRV has focused on refractory epilepsy and only a few studies have provided preliminary insights about BRV use in special populations [ 4 – 6 ] and in the early stages of treatment [ 7 ]. There is, hence, little information about the effectiveness of BRV when it is administered as a first or second add-on therapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Brivaracetam as Early Add-On Treatment in Patients with Focal Seizures: A Retrospective, Multicenter, Real-World Study

et al. 2022

Self Cite

View full text Add to dashboard Cite

Introduction:In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure frequency in patients with drug-resistant focal epilepsy. Most real-world research on BRV has focused on refractory epilepsy. The aim of this analysis was to assess the 12-month effectiveness and tolerability of adjunctive BRV when used as early or late adjunctive treatment in patients included in the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST). Methods: BRIVAFIRST was a 12-month retrospective, multicenter study including adult patients prescribed adjunctive BRV. Effective-The members of the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST) Group are listed in the Acknowledgements section.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Brivaracetam as Early Add-On Treatment in Patients with Focal Seizures: A Retrospective, Multicenter, Real-World Study

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Since the EXPERIENCE analysis was undertaken, outcomes of a subgroup analysis of patients with post-stroke epilepsy from the retrospective observational BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST) [ 34 ] have been published. In EXPERIENCE, the percentage of patients with post-stroke epilepsy who achieved ≥ 50% seizure reduction at 12 months was higher than in BRIVAFIRST (50.0% vs 41.7%).…”

Section: Discussionmentioning

confidence: 99%

Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis

Szaflarski,

Besson,

D’Souza

et al. 2024

J Neurol

View full text Add to dashboard Cite

Objective To assess the effectiveness and tolerability of brivaracetam (BRV) in adults with epilepsy by specific comorbidities and epilepsy etiologies. Methods EXPERIENCE/EPD332 was a pooled analysis of individual patient records from several non-interventional studies of patients with epilepsy initiating BRV in clinical practice. Outcomes included ≥ 50% reduction from baseline in seizure frequency, seizure freedom (no seizures within prior 3 months), continuous seizure freedom (no seizures since baseline), BRV discontinuation, and treatment-emergent adverse events (TEAEs) at 3, 6, and 12 months. Analyses were performed for all adult patients (≥ 16 years of age) and stratified by comorbidity and by etiology at baseline (patients with cognitive/learning disability [CLD], psychiatric comorbidity, post-stroke epilepsy, brain tumor−related epilepsy [BTRE], and traumatic brain injury−related epilepsy [TBIE]). Results At 12 months, ≥ 50% seizure reduction was achieved in 35.6% (n = 264), 38.7% (n = 310), 41.7% (n = 24), 34.1% (n = 41), and 50.0% (n = 28) of patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE, respectively; and continuous seizure freedom was achieved in 5.7% (n = 318), 13.7% (n = 424), 29.4% (n = 34), 11.4% (n = 44), and 13.8% (n = 29), respectively. During the study follow-up, in patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE, 37.1% (n = 403), 30.7% (n = 605), 33.3% (n = 51), 39.7% (n = 68), and 27.1% (n = 49) of patients discontinued BRV, respectively; and TEAEs since prior visit at 12 months were reported in 11.3% (n = 283), 10.0% (n = 410), 16.7% (n = 36), 12.5% (n = 48), and 3.0% (n = 33), respectively. Conclusions BRV as prescribed in the real world is effective and well tolerated among patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE.

show abstract

“…The study’s findings suggest that adjunctive BRV holds promise as a viable therapeutic option for patients with post-stroke epilepsy. 26 The BRIVAFIRST study, conducted retrospectively across 63 Italian centres, focused on adult patients aged 16 years and older who were prescribed BRV as an add-on treatment. The analysis of BRIVAFIRST data revealed that adjunctive BRV provided clinical benefits for a specific subset of patients with highly active and challenging-to-treat focal epilepsy.…”

Section: Discussionmentioning

confidence: 99%

A prospective, observational, multicentre study to evaluate the efficacy of brivaracetam as adjuvant therapy for epilepsy: The Bravo study

Siddiqui,

Soomro,

Rehman

et al. 2024

DIC

View full text Add to dashboard Cite

Brivaracetam as add-on treatment in patients with post-stroke epilepsy: real-world data from the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST)

Cited by 9 publications

References 19 publications

Brivaracetam as Early Add-On Treatment in Patients with Focal Seizures: A Retrospective, Multicenter, Real-World Study

Brivaracetam as Early Add-On Treatment in Patients with Focal Seizures: A Retrospective, Multicenter, Real-World Study

Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis

A prospective, observational, multicentre study to evaluate the efficacy of brivaracetam as adjuvant therapy for epilepsy: The Bravo study

Contact Info

Product

Resources

About